A Phase IV, Single blind randomized, multicentric study

Abstract: 

A Phase IV, Single blind randomized, multicentric study to demonstrate the non-inferiority in terms of immunogenicity of multidose ENGERIX B with 2 - phenoxyethanol as preservative to that elicited by multidose ENGERIX B with thimersal as preservative, when administered according to a 0, 1 and 6 months schedule in health adults aged greater than 18 years